Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Interest & Investment Income (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Interest & Investment Income data on record, last reported at $3.1 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 38.85% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $15.1 million, down 22.6%, while the annual FY2025 figure was $15.1 million, 22.6% down from the prior year.
  • Interest & Investment Income reached $3.1 million in Q4 2025 per TRDA's latest filing, down from $3.6 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $5.8 million in Q3 2024 and bottomed at $403000.0 in Q2 2022.
  • Average Interest & Investment Income over 4 years is $3.3 million, with a median of $4.0 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: soared 946.65% in 2023, then plummeted 38.85% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $950000.0 in 2022, then skyrocketed by 351.79% to $4.3 million in 2023, then increased by 19.48% to $5.1 million in 2024, then tumbled by 38.85% to $3.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $3.1 million in Q4 2025, $3.6 million in Q3 2025, and $3.9 million in Q2 2025.